Controlled Level EVERolimus in Acute Coronary Syndromes
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT01529554
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 150 participants
- Registry
-
NCT01529554
-
- Other papers using this trial's data
- Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial
- Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction
- Microcirculatory Resistance After Primary Percutaneous Coronary Intervention Predicts Residual Myocardial Damage and Scar Formation
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT01529554. Randomized; quadruple masking; primary purpose treatment. Start 2015-01-08 (actual); primary completion 2021-11-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Controlled Level EVERolimus in Acute Coronary Syndromes
- Acronym
- CLEVER-ACS
- Condition
- Acute Coronary Syndromes
- Intervention (Drug)
- Everolimus
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Zurich
- Collaborator
- Swiss National Science Foundation
- Collaborator
- Novartis
Record details
- Record id
cardio:ct-nct01529554- Content hash
2cbb5ed1f978cb8d809a53ffd5545ef8ec8212ff8afdcdfc29c4e10f53dd66fe